BILL ANALYSIS

HR3164

NEUTRAL

Ensuring Community Access to Pharmacist Services Act

HR3164 (Ensuring Community Access to Pharmacist Services Act) has been assessed with a neutral outlook for investors. This legislation directly affects CVS Health ($CVS). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR3164 has been stalled for nearly a year with zero committee action since referral

No funding mechanism exists in the bill — it is an authorization-only policy change

CVS and UNH recent price gains are driven by broad sector momentum, not this legislation

Even if passed, implementation would take 12-24 months via HHS rulemaking

110 cosponsors show bipartisan support, but early-stage status with no hearings limits impact

How HR3164 Affects the Market

No near-term market implications from HR3164. CVS ($82.96) and UNH ($366.77) are trading on earnings fundamentals and sector rotation, not this bill. The bill has had zero legislative progress in 364 days. Retail investors should not factor this legislation into any current trading decisions. Monitor for committee hearings or a funding rider as catalysts, but treat HR3164 as noise until it moves from referral to markup.

Bill Details

Metric	Value
Bill Number	HR3164
Market Sentiment	neutral
Event Date	May 1, 2025
Affected Sectors	Healthcare
Affected Stocks	CVS Health ($CVS)
Source	View on Congress.gov →

Summary

HR3164 (Ensuring Community Access to Pharmacist Services Act) remains in early committee stage with no funding mechanism. CVS at $82.96 (+6.44% 7-day) and UNH at $366.77 — both moves driven by broader sector momentum, not this specific bill. No measurable near-term revenue impact for any company.

Full AI Market Analysis

What happened: HR3164 was introduced on May 1, 2025 by Rep. Adrian Smith (R-NE) with 110 cosponsors and referred to both the Energy & Commerce and Ways & Means Committees. As of today (April 30, 2026), the bill has had only 4 actions — all on the same day of introduction — with no committee hearings, markups, or further movement. This is a classic early-stage authorization bill with zero legislative velocity. The money trail: This bill is an AUTHORIZATION bill that amends the Social Security Act to expand Medicare Part B coverage definitions. There is ZERO funding attached — no dollar amount, no tax, no fee, no appropriation. Authorization bills set policy ceilings; actual federal spending requires a separate appropriations bill. Even if passed, HHS would need to issue regulations and CMS would need to set fee schedules, a process taking 12-24 months minimum before any revenue flows. Structural winners and losers: If the bill were to pass and be funded, retail pharmacy chains with large pharmacist workforces (CVS, Walgreens Boots Alliance at $WBA, Rite Aid/HIV living trust, and independents) would gain a new Part B revenue stream. PBMs (Optum Rx/UNH, CVS Caremark/CVS, Express Scripts/$CI) would benefit from increased pharmacy visit volume driving prescription fulfillment. However, physician groups would face new competition for basic testing and treatment visits. None of this is near-term or funded. Real market data analysis: CVS has rallied from $77.30 on April 17 to $82.96 on April 30 — a 7.3% gain excluding the single-day drop to $76.43 on April 22. This is part of a broader healthcare sector move (UNH up 41.6% in 30 days) driven by Q1 earnings optimism, not this bill. The bill has seen zero legislative action for 364 days. Retail investors should not attribute any of CVS or UNH's recent price action to HR3164. Timeline: The bill needs at least: (1) committee hearings and markups in both Energy & Commerce and Ways & Means, (2) House floor vote, (3) Senate companion bill (S2426 is in Senate Finance) passage, (4) conference committee, (5) presidential signature, (6) HHS rulemaking. At current velocity, this is a multi-year timeline at best. Zero legislative actions in the past 12 months indicate no near-term path.